Search results
FDA approves generic Emflaza oral suspension for Duchenne muscular dystrophy
Medical Xpress· 13 hours agoThe U.S. Food and Drug Administration has approved the first generic version of Emflaza...
Study finds LED therapy and antioxidant drug benefit muscle regeneration in Duchenne muscular ...
Medical Xpress· 3 days agoAs reported in an article published in the journal PLOS ONE, the strategy prevented muscle...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with ...
Morningstar· 5 days ago(NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene ...
Pfizer's Duchenne Muscular Dystrophy Treatment Misses Endpoints
Morningstar· 5 days agoPfizer's gene therapy being developed to treat Duchenne muscular dystrophy missed its primary endpoint in a late-stage trial. The pharmaceutical ...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 4 days agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Pfizer gene therapy for Duchenne fails to meet goals of key trial
BioPharma Dive via Yahoo Finance· 5 days agoThe negative results from the Phase 3 study, called Ciffreo, come a little more than a month after...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Zacks via Yahoo Finance· 4 days agoPfizer’s PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for...
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 5 days agoPfizer Inc. said late Wednesday that its experimental gene therapy for Duchenne muscular dystrophy...
MarionMade!: Running to help others who may not be able to walk
The Marion Star via Yahoo News· 2 days agoThe family then started My DMD hero in 2019 to help other families. “The goal is to meet Duchenne...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 5 days agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...